NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q2 2024 vs. Q1 2024
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 8 | 7 | −1 |
| Shares | 167.1K | 1.67M | +1.50M (+899.9%) |
| Value | $303.9K | $1.87M | +$1.57M (+515.8%) |
New holders (2)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 1,584,000 | $1.77M | 0.05% |
| XTX Topco Ltd | 32,650 | $36.6K | 0.00% |
Sold out (3)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Renaissance Technologies LLC | 71,100 | $129.0K |
| Woodline Partners LP | 19,581 | $35.6K |
| UBS Group AG | 11,928 | $21.7K |